home / stock / mdwd / mdwd news

MDWD News and Press, MediWound Ltd. From 03/03/22

Stock Information
Company Name: MediWound Ltd.
Stock Symbol: MDWD
Market: NASDAQ
Website: mediwound.com
Menu
MDWD MDWD Quote MDWD Short MDWD News MDWD Articles MDWD Message Board
Get MDWD Alerts

News, Short Squeeze, Breakout and More Instantly...
MDWD - MediWound Announces Pricing of Public Offering of Ordinary Shares

YAVNE, Israel, March 03, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration, today announced the pr...
MDWD - MediWound slides on proposed stock offering

MediWound (NASDAQ:MDWD), a commercial-stage pharmaceutical company focused on tissue repair and regeneration, has lost ~29% in the post-market Wednesday after announcing a proposed underwritten public offering of ordinary shares. A 30-day option allowing underwriters to purchase up ...

MDWD - MediWound Ltd. Announces Proposed Public Offering of Ordinary Shares

YAVNE, Israel, March 02, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“Mediwound”), a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration, today announced that i...

MDWD - MediWound to Present at Upcoming Investor Conferences in March

YAVNE, Israel, March 01, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that management would present at two upcoming investor confer...
MDWD - MediWound Awarded a U.S. Department of Defense Research Grant for the Development of NexoBrid for the U.S. Army

YAVNE, Israel, Feb. 17, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio therapeutic solutions for tissue repair and regeneration, today announced that the U.S. Department of Defense (DoD), through the Medica...

MDWD - MediWound to Present at Upcoming Investor Conferences in February

YAVNE, Israel, Feb. 14, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that management would present at two upcoming investor confere...

MDWD - MediWound wins $9M additional BARDA funding for NexoBrid

MediWound (NASDAQ:MDWD) is trading ~7% higher in the pre-market on Thursday after announcing that the Biomedical Advanced Research and Development Authority (BARDA) provided the company with $9M supplemental funding expanding its contract for NexoBrid. The additional funding is inte...
MDWD - MediWound Announces Additional $9 Million in Funding from BARDA to Support NexoBrid BLA Resubmission and the Expanded Access Treatment Protocol

YAVNE, Israel, Feb. 10, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that the Biomedical Advanced Research and Development Authorit...

MDWD - MediWound Announces Positive Topline Results From Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds

Primary Endpoint Met with Highly Statistically Significant Results No Observed Safety Issues Final Data R eadout Expected in Second Quarter of 2022 YAVNE, Israel, Jan. 24, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integra...

MDWD - MediWound reports positive initial data from Phase 2 EscharEx study in chronic, hard to heal wounds

MediWound (NASDAQ:MDWD) announces positive initial data from seven of the maximum fifteen patients in its ongoing Phase 2 pharmacology study of EscharEx, the company’s next-generation enzymatic debridement agent under development for chronic and hard-to-heal wounds. Shares up 2.5%...
Previous 10 Next 10